{"doi":"10.1101/2020.02.03.932129","title":"Leukotriene B <sub>4</sub> licenses inflammasome activation to enhance skin host defense","abstract":"Abstract The initial production of inflammatory mediators dictates host defense as well as tissue injury. Inflammasome activation is a constituent of the inflammatory response by recognizing pathogen and host-derived products and eliciting the production of IL-1β, IL-18 as well as inducing a type of inflammatory cell death termed “pyroptosis”. Leukotriene B 4 (LTB 4 ) is a lipid mediator produced quickly (seconds to minutes) by phagocytes and induces chemotaxis, enhances cytokine/chemokine production, and enhances antimicrobial effector functions. Whether LTB 4 directly activates the inflammasome is not well understood. Our data show that endogenously produced LTB 4 is required for the expression of pro-IL-1β in vivo and in vitro and enhances inflammasome assembly. Furthermore, LTB 4 -mediated Bruton’s tyrosine kinase (BTK) activation is required for inflammasome assembly in vivo as well for IL-1β-enhanced skin host defense. Together, these data unveil a new role for LTB 4 in enhancing the expression and assembly of inflammasome components and suggest that while blocking LTB 4 actions could be a promising therapeutic strategy to prevent inflammasome-mediated diseases, exogenous LTB 4 can be used as an adjuvant to boost inflammasome-dependent host defense.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2020,"id":128833,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9605,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":489984,"name":"Stephanie L. Brandt","orcid":"0000-0002-4865-1019","position":1,"is_corresponding":false},{"id":491105,"name":"Nathan Klopfenstein","orcid":null,"position":2,"is_corresponding":false},{"id":428985,"name":"Amondrea Blackman","orcid":"0000-0003-0785-938X","position":3,"is_corresponding":false},{"id":491106,"name":"Nicole Byers-Glosson","orcid":null,"position":4,"is_corresponding":false},{"id":489986,"name":"Cláudia Brodskyn","orcid":"0000-0003-3367-5365","position":5,"is_corresponding":false},{"id":489987,"name":"Natália Machado Tavares","orcid":"0000-0002-4026-679X","position":6,"is_corresponding":false},{"id":489988,"name":"Ícaro Bonyek-Silva","orcid":"0000-0002-0346-9360","position":7,"is_corresponding":false},{"id":489989,"name":"Alexandra Ivo de Medeiros","orcid":"0000-0001-6048-3647","position":8,"is_corresponding":false},{"id":489990,"name":"C. Henrique Serezani","orcid":"0000-0002-5363-415X","position":9,"is_corresponding":false},{"id":489983,"name":"Ana Carolina Guerta Salina","orcid":"0000-0003-3220-0413","position":0,"is_corresponding":true}],"reference_count":61,"raw_metadata":null,"created_at":"2026-07-18T23:15:42.522809Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}